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Abstract 
Cancer is one of the most important reasons of mortality in the world. However, there are several therapeutic plat-
forms to treat patients who suffering from cancer common treatments such as surgery, chemotherapy and etc. 
The current therapeutic approaches are related to some limitations. Hence, more understanding about molecular 
mechanisms that involved in cancer particularly in breast cancer pathogenesis, could contribute to provide better 
therapeutic platforms. Recently, non-coding RNAs such as microRNAs have attracted researchers’ attention in the field 
of cancer due to their functions in gene expression’s regulation and functional interactions with other molecules. 
Interestingly, great advances in next-generation sequencing lead to considering other roles for another non-coding 
RNAs subgroup called PIWI-interacting RNAs (piRNAs) in addition to their functions in the germline. Novel studies 
investigated the role of piRNAs in several cancers including lung cancer, hepatocellular carcinoma, gastric cancer, 
multiple myeloma and colorectal cancer. Hopefully, based on new findings, piRNAs may be a potential biomarker 
which can be used as a tool to diagnose or treat breast cancer. Thus, this review aimed to discuss the role of piRNAs in 
breast cancer progression and metastasis as well as its molecular mechanisms.
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Background
Breast disorders are very important disorders among 
women [1]. Among them, Breast cancer is the most 
common malignancy among women and it is the prin-
ciple cause of women’s death all over the world. In spite 
of great progress in the ield of cancer, breast cancer is 
still a serious health problem among women which has 
complicated properties heterogeneously and shows a 
number of biological and clinical manifestations [2–4]. 
Breast cancer has been categorized into ive groups based 
on expression patterns of three receptors: the estrogen 
receptor, progesterone receptor and human epidermal 
growth factor receptor. his categorization was a helpful 
way in order to predict the outcome and choose the best 
treatment option [5, 6]. Mutations in BRCA1 and BRCA2 
are some examples of genomic instabilities which are the 
most prominent cause of breast cancer [7–9]. Several 
studies indicated that a variety of techniques could be 
used in the treatment of diferent cancers such as breast 
cancer (i.e., cell-, gene-, and nanotechnology-based ther-
apies) [10–17]. Despite emerging new and efective ther-
apeutic platforms in the treatment of breast cancer, new 
approaches are needed [18, 19]. In this regard, it seems 
that more understanding of cellular and molecular path-
ways involved in breast cancer pathogenesis could con-
tribute to the development of new therapies [18].
In the past, scientists called 98% non-protein coding 
human genome as “junk” DNA. hese DNAs produce 
RNAs which are not translated into proteins. his group 
is known as non-coding RNAs (non-encoding RNAs) 
which has two main subgroups: regulatory non-coding 
RNAs and housekeeping non-coding RNAs. he regula-
tory non-coding RNAs are also sorted into two subdivi-
sions by their length: short chain non-coding RNAs and 
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